A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 May 2018
At a glance
- Drugs HTI 1090 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 21 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Sep 2018.
- 09 Nov 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2017 New trial record